Purpose: To compare 3-year iontophoretic corneal collagen cross-linking (I-CXL) outcomes with epithelium-off corneal collagen cross-linking (epi-off CXL) for early stage of progressive keratoconus. Methods: Eighty eyes of 80 patients with early progressive keratoconus treated by I-CXL (n = 40) or epi-off CXL (n = 40) were included in this study. Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, corneal topography and pachymetry were assessed at baseline and at 1, 3, 6, 12, 24 and 36 months of follow-up. Results: Visual acuity (VA) showed a significant improvement (p < 0.05) at the end of follow-up in both groups. In the I-CXL group, the UDVA showed a rapid recovery after 3 months (p = 0.04). There was a statistically significant different trend in CDVA between groups with a more favourable outcome for the standard CXL group (p < 0.01). The cylinder improved beginning with 3 months after CXL in both groups. Maximum keratometry showed a significant reduction by 0.9 dioptres (D) in the I-CXL group and by 1.2 D in the epi-off CXL group after 36 months (p = 0.283). Pachymetry values decreased at 3 months while a statistically significant increase occurred in both groups at 24 months. Progression occurred to one patient (2.5%) in I-CXL group. Adverse effects occurred to eight eyes (20%) in the epi-off CXL group. Conclusion: Iontophoretic corneal collagen cross-linking (I-CXL) is noninferior to epi-off CXL for stopping the progression of keratoconus in its early stages with a higher degree of safety for the patients and a faster recovery of VA.
Introduction
Riboflavin-ultraviolet A (UVA)-induced corneal collagen cross-linking is the procedure of choice used to stabilize the progression of keratoconus. Introduced in 2003 by Wollensak, this procedure proved efficient for keratoconus treatment and secondary ectasia on longterm, and reduced the need for corneal transplants (Wollensak et al. 2003; Godefrooij et al. 2016) . Also known as the Dresden protocol, the standard technique for cross-linking requires the removal of the corneal epithelium to allow riboflavin to deeply penetrate the stroma and, under UVA action, to generate new collagen cross-links with effects on 'stiffening' the cornea (Wollensak et al. 2003; Wollensak 2006) .
As the epithelium debridement is responsible for most complications related to cross-linking (postoperative pain, haze, keratitis, sterile infiltrates and low VA), efforts were made to give up on this stage (Greenstein et al. 2010; Rama et al. 2011; C ß erman et al. 2016) .
It was found that dextran-enriched riboflavin cannot penetrate the intact epithelium; therefore, different versions of standard cross-linking procedure have been developed aiming at preserving the corneal epithelium, thereby reducing the complications rate and postoperative pain.
Although the transepithelial crosslinking using a riboflavin solution enriched with ethylene diamine tetraacetic acid (EDTA) and trometamol was initially hailed, this has not proved its long-term efficiency, as the continuous progression of keratoconus was reported after 1 year of treatment. (Caporossi et al. 2013; Torricelli et al. 2014; Rossi et al. 2015; Shalchi et al. 2015) . Other methods aimed at increasing the penetration of riboflavin into the corneal stroma, such as removing the superficial epithelium with the excimer laser (Bakke et al. 2009 ), injecting riboflavin in an intrastromal 'pocket' created by femto-lasers (Kanellopoulos 2009) or iontophoresis were experienced.
Iontophoresis is a non-invasive method by which a substance can penetrate the tissues under the influence of an electric current of low intensity. Riboflavin used for iontophoresis is a low molecular weight substance, negatively charged and water-soluble. Ex vivo studies showed that a satisfactory imbibition of riboflavin into the corneal stroma, superior to that obtained by transepithelial cross-linking, but lower than that of the standard technique of cross-linking, can be obtained by the use of iontophoresis (Mencucci et al. 2015) . The effect of stiffening the cornea was comparable to that achieved by the standard epithelium-off technique (Bakke et al. 2009; Mastropasqua et al. 2014a,b; Cassagne et al. 2016) .
Recent clinical trials have reported promising results of corneal crosslinking by iontophoresis; this allows disease stabilization compared with standard cross-linking, but with a more rapid improvement of functional parameters and with significantly lower side-effects (Bikbova & Bikbov 2014; Vinciguerra et al. 2014) . So far, data are reported after maximum 2-year follow-up; the technique proved to be extremely useful in the early stages of the disease (Cantemir et al. 2017) .
The reported results are not entirely consistent. A prospective, randomized study led by Jouve concludes that cross-linking by iontophoresis is less effective to halt the progression of keratoconus, compared with the standard epithelium-off cross-linking in 2-year follow-up of patients (Jouve et al. 2017) .
Recent data have shown that accelerated cross-linking provides results similar to conventional cross-linking to stabilize keratoconus, having the advantage of a lower exposure to ultraviolet and increased patient comfort (Chow et al. 2015; Waszczykowska & Jurowski 2015) .
In this study, we assessed the threeyear outcomes of I-CXL compared to those of the epi-off CXL, the accelerated protocol, in patients with early progressive keratoconus.
Materials and Methods
In this retrospective, comparative clinical study, we included 80 eyes of 80 patients with early progressive keratoconus who attended the Oftaprof Clinic of Iasi, Romania, between 1 January 2012 and 31 July 2016. We evaluated 40 eyes of 40 patients who received I-CXL treatment who were compared with a matched analysis on 40 eyes from 40 different patients who underwent epi-off CXL. The patients were identified by computerized clinic record system; the follow-up was 3 years for every patient. The study was approved by the local ethics committee and was conducted accordingly to the ethical standards set by the 1964 Declaration of Helsinki, as revised in 2003. All patients provided informed consent at the time of the procedure. Keratoconus diagnosis and the need for treatment were assessed by two corneal specialists (AC, DC).
Patients
The inclusion criteria were as follows: age 18 and over, keratoconus stage 0 and I according to the Belin ABCD classification (Duncan et al. 2016) , documented progressive nature of the disease and endothelial cell density (ECD) higher than 2000 cells/mm 2 . Progression indicating the need for treatment was defined by an increase in the maximum keratometry by at least 1 D or by an increase in the manifest cylinder of 1 D over the preceding 12 months, documented by repeated Scheimpflug corneal topographies.
The study excluded patients diagnosed with diabetes, immune system diseases and other ocular corneal disorders (herpetic keratitis, dry eye syndrome and corneal scarring), central corneal thickness (CCT) <400 lm at the thinnest point. Other exclusion criteria were pregnancy or breastfeeding.
Visits
All patients were examined at baseline and at 1, 3, 6, 12, 24 and 36 months after intervention. The following measurements were performed at baseline and at each follow-up visit: slit-lamp examination of the anterior segment of the eye, UDVA (logMAR units), CDVA (logMAR units), manifest refraction (expressed as sphere and cylinder, D), keratometry (K min and K max ) assessed by optical tomography (Pentacam, Oculus Optikger€ ate GmbH, Wetzlar, Germany), ultrasonic pachymetry for corneal thickness at the thinnest point (CTTP), endothelial cell count (ECC; Konan Specular Microscope; Konan Medical, Inc., Hyogo, Japan) and intra-ocular pressure (IOP) by Goldmann applanation tonometry. The postoperative demarcation line depth was measured 1 month after intervention by anterior segment optical coherence tomography (AS-OCT, Visante OCT; Carl Zeiss Meditec, Jena, Germany).
Procedures
Collagen cross-linking (CXL) by iontophoresis was performed for 40 eyes (40 patients) included in the study. Pilocarpine 1% drops were instilled 30 min prior to the procedure, to reduce the risk for ultraviolet light exposure of the lens and retina. The procedure was performed under topical anaesthesia with three applications of 4% lidocaine drops under sterile conditions during 15 min, using a commercial iontophoresis device (Iontophor CXL, SOOFT Italia SpA, Italy). A special ring applicator containing the active electrode (stainless steel mesh) was applied to the corneal surface, and a patch containing the passive electrode was applied to the forehead. A continuous current generator (I-ON XL, SOOFT) set at 1 mA, powered by batteries, was connected to the relevant cables (Fig. 1) . The applicator was filled with 0.5 ml hypotonic solution of riboflavin (Ricrolin+; SOOFT, Montegiorgio, Italy) and the corneas underwent imbibition for 5 min. After iontophoresis, the corneal surface was washed with 0.9% sodium chloride solution. The corneas were irradiated with an ultraviolet lamp [CBM VEGA 10 mW UVA Illumination System, Construzione Strumenti Oftalmici (CSO), Firenze, Italy] with a wavelength of 370 nm for 9 min at 10 mW at a distance of 45 mm. After surgery, a bandage contact lens was applied and it was removed after 48 hr. Postintervention, patients received tobramycin-dexamethasone drops (Tobradex, Alcon) and artificial tears (Blu Yal, SOOFT), four times daily for 4 weeks.
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Acta Ophthalmologica 2017 Epithelium-off corneal collagen cross-linking (epi-off CXL) was performed for 40 eyes of 40 patients with stage I keratoconus. Epithelial removal was performed using a blunt knife, then, iso-osmolar riboflavin 0.1% solution with 20% dextran (Ricrolin; SOOFT, Montegiorgio, Italy) was applied every 3 min for 15 min, to fully irrigate the cornea. Irradiation was performed with a UVA lamp (CBM VEGA 10 mW UVA Illumination System) with a wavelength of 370 nm for 9 min at 10 mW at a distance of 45 mm. A bandage contact lens was placed after procedure, and it was removed after the epithelial healing was documented. The post-CXL medication consisted of tobramycin eye drops (Tobrex, Alcon) and artificial tears (Blu Yal, SOOFT), five times daily until epithelial healing was documented, followed by tobramycin-dexamethasone drops (Tobradex, Alcon) and artificial tears (Blu Yal, SOOFT), four times daily for 3 more weeks.
Statistical analysis
Statistical analysis was performed using the SPSS statistical software (version 20.0; IBM Corp., Armonk, NY, USA). Data are described as mean AE standard deviation. A p-value of <0.05 was considered significant in all cases.
Baseline measurements between groups were compared using an independent sample t-test. The Student's t-test for paired data was used to compare preoperative and postoperative parameters. Measurements between groups at each time-point were compared using an independent sample t-test.
The data in our cohorts do not have a normal distribution (according to Kolmogorov-Smirnov and Shapiro-Wilk tests); despite this, we employed parametric (and not non-parametric) tests because the samples of the cohorts are balanced (40 subjects in each cohort).
To report the trend over time, a variance analysis, the general linear model repeated measures was used by applying the polynomial option wherein seven time-points (baseline, 1, 3, 6, 12, 24 and 36 months) were used as categorical variables.
Results
This retrospective study compared the evolution over 36 months of two groups with cross-linking for progressive keratoconus each including 40 eyes of 40 patients: the epi-off CXL group and I-CXL group. The groups were comparable, with no significant differences regarding the used demographic and clinical parameters. The mean age was 26.5 AE 3.7 (range 18-34) for the epi-off CXL group and 28.3 AE 4.9 (range 18-35) for I-CXL group. Most patients were men in both groups. The baseline characteristics of the two groups are presented in Table 1 .
Adverse effects occurred to eight eyes (20%) within the epi-off CXL group: five cases of corneal haze, two cases of delayed re-epithelization and one case of sterile infiltrate. Complications were solved without sequelae in all cases. All patients in I-CXL group manifested a superficial punctate keratitis the first day after CXL which vanished after 48 hr. There was no postoperative complication in I-CXL group.
At the end of the follow-up, the disease stabilization was achieved in all eyes after epi-off CXL treatment. Progression occurred to one patient (2.5%) in I-CXL group to whom the disease stabilization was documented at 24 months.
Visual acuity
The UDVA began to improve rapidly in I-CXL group, starting with 3 months postoperatively, and being significantly higher in this group in the first 24 months of follow-up (p = 0.022).
The mean UDVA increased with 1.7 Snellen lines in I-CXL group and with 1.1 lines in the epi-off CXL group at 36 months postoperatively; at this point, the difference between groups did not reach the statistical significance threshold (p = 0.064; Table 2 and Fig. 2A) .
The CDVA evolved differently within the two treatment groups: it remained stable at 1 and 3 months postoperatively, with a statistically significant increase starting with the 6-month visit (p = 0.037) in I-CXL group. After an initial decline, one month after surgery, CDVA began to increase starting with the 6-month visit in the epi-off CXL group (p = 0.038; Table 2 and Fig. 2B ). The CDVA continued to improve throughout the last follow-up in both groups. The CDVA trend towards improvement assessed by general linear model was significantly higher in the epi-off CXL group (p = 0.001; Table 2 and Fig. 2B ).
Refractive parameters
Values of the manifest sphere have not experienced any changes in the groups in the first 12 months follow-up; manifest sphere decreased in both groups A decline of the manifest cylinder occurred at 3 months after CXL in both groups, the improvement continued for the remainder of the follow-up. There were no statistically significant differences regarding the trends over time towards improvement of the cylinder between the two groups (p = 0.883; Table 2 and Fig. 3) . CDVA = corrected distance visual acuity, CTTP = corneal thickness at the thinnest point, epi-off CXL = epithelium-off corneal collagen cross-linking, I-CXL = iontophoresis collagen cross-linking, K max = maximum keratometry, K min = minimum keratometry, UDVA = uncorrected visual acuity. * p < 0.05 statistically significant difference compared to baseline.
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Keratometry
A decrease in K max values occurred 6 months postoperatively in both groups. Flattening the cornea continued throughout the follow-up, with no statistically significant difference between groups at any time-frame. At 36 months postoperatively, the K max decline was 1.2 D for the epi-off CXL group and 0.9 D for the I-CXL group, with no any statistically significant difference (p = 0.283; Table 2 and Fig. 4) . No significant flattening of K min values occurred in any of the groups throughout the follow-up.
Pachymetry
Both groups showed a significant decrease in the CTTP from the baseline values at 3 months postoperatively; subsequently, the pachymetry values returned to preoperative levels at 12 months, while a statistically significant increase occurred in both I-CXL and epi-off CXL groups (p = 0.02, p = 0.012) at 24 months. There were no significant differences in trends over time between the groups (p = 0.574; Table 2 and Fig. 5 ).
Anterior segment optical coherence tomography (AS-OCT) was performed in all patients 1 month postoperatively; the demarcation line was identified in 90% of the epi-off CXL group patients with an average depth of 286 AE 24 lm. Only an increase in anterior stroma reflectance was noted in all patients within the I-CXL group; a sharp demarcation line was clearly identified only in 10% of cases, with an average depth of 134 AE 23 lm.
No significant difference of ECC and IOP occurred within the groups throughout the follow-up.
Discussion
Standard epi-off CXL proved its efficiency in halting the progression of keratoconus during long-term follow-up studies to 10 years (Hashemi et al. 2013; Wittig-Silva et al. 2014; Raiskup et al. 2015) . Iontophoretic collagen cross-linking (I-CXL) has the advantage of maintaining the corneal epithelium and of reducing the frequency of side-effects.
Recent clinical trials have shown that I -CXL is a valid method to halt the progression of keratoconus with an improvement of clinical and paraclinical parameters, but with a lower efficacy compared to standard crosslinking (Bikbova & Bikbov 2016; Vinciguerra et al. 2016; Jouve et al. 2017) .
In the present study, we reported the long-term results of I-CXL compared with epi-off CXL for the treatment of early keratoconus. To our knowledge, this is the first study that compares the I-CXL with epi-off CXL in terms of efficacy and safety with a follow-up period of 36 months. All patients who took part in the study had keratoconus of stage 0 and I according to Belin ABCD classification, the compared groups being homogeneous.
Our study demonstrated a faster and more important recovery of UDVA in I-CXL group versus the epi-off CXL. Although CDVA had a faster increase in I-CXL group, the CDVA trend towards improvement assessed was significantly higher in the epi-off CXL group (p = 0.001; Table 2 and Fig. 2B) . The results are consistent with those reported by other studies, noting that our patients are followed up for a longer period of time (Bikbova & Bikbov 2016; Vinciguerra et al. 2016; Jouve et al. 2017) .
The examined refractive parameters improved in both treatment groups: the manifest cylinder began to decrease 3 months after cross-linking, continuing throughout the next 24-month follow-up and keeping stable up to 36 postoperative months.
The regression of maximum keratometry values was observed in both groups at the 12 months' follow-up visit and continued for the remaining follow-up period, without any statistically significant difference between the two groups. Our results are consistent with those achieved by other studies which demonstrated stabilization or improvement of cylinder and keratometry values and, therefore, the disease stabilization (Bikbova & Bikbov 2016; Vinciguerra et al. 2016; Jouve et al. 2017) .
Although after 24-month follow-up the disease stabilization was achieved in all patients, progression was noticed in one of the patients treated with I-CXL at 36 months. One possible explanation was the occurrence of an allergic conjunctivitis and eye rubbing during the past year. This finding focuses on the importance of patients' longer follow-up after the cross-linking treatment, 24 months being insufficient to prove the disease stabilization.
A recent study led by Jouve indicates a 7.5% failure rate of treatment for standard cross-linking and 20% for I-CXL after 2 years of follow-up. However, the authors suggest that I-CXL should be the method of choice in patients with thin corneas and intolerance to pain. Studed groups differ from ours, patients with more advanced stages of keratoconus with a faster progress (2.2 average Amsler score) being included (Jouve et al. 2017) .
The fact that all patients were in an early stage of the disease could be one explanation for the fact that the improvement of their paraclinical indices to become more evident in our study. The pachymetry readings decreased in both groups starting with 3 postoperative months; these subsequently reached their preoperative level, at 12 months postoperatively, without statistically significant differences between the two groups.
The evolution of pachymetry is comparable to that reported by other studies; the specific of our groups is represented by high preoperative values due to the early stage of the disease (Bikbova & Bikbov 2016; Vinciguerra et al. 2016; Jouve et al. 2017) . Adverse events were observed during the early postoperative period only within the epi-off CXL group, but they did not affect the long-term prognosis of patients in this group. No statistically significant changes in endothelial cells density and in IOP in any of the studied groups were observed. The rapid improvement of UDVA and CDVA, together with the absence of postoperative complications is important advantages of I-CXL, as they allow a faster recovery and an early work reintegration. Our results are consistent with those reported by other authors related to the increased safety of I-CXL compared to the standard technique of CXL (Bikbova & Bikbov 2016; Vinciguerra et al. 2016; Jouve et al. 2017) .
Anterior segment optical coherence tomography (AS-OCT) was performed in all patients included in the study at the 1-month follow-up visit; the demarcation line was identified in 90% of patients of the epi-off CXL group with an average depth of 286 AE 24 lm.
The demarcation line was clearly identified only in 15% of cases in I-CXL group, with an average depth of 134 AE 23 lm. Most often, only an increased reflectance of anterior stroma was observed.
Using the same protocol, our results are consistent with those reported by Vinciguerra et al. (2014) which did not identify a clear demarcation line in the cornea treated with I-CXL. On the other hand, Bikbova & Bikbov (2016) identified a demarcation line in 45% of patients undergoing cross-linking by iontophoresis; this is probably due to the use of a different protocol with riboflavin impregnation time of 10 min, followed by irradiation for 30 min.
Based on preclinical studies, it is already established that the penetration of riboflavin and the biomechanical stabilizing effect of I-CXL treatment are higher than the transepithelial cross-linking, but still lower than standard cross-linking (Mastropasqua et al. 2014b; Bikbova & Bikbov 2016; Hayes et al. 2016) . Previously reported data suggest that there is no clear correlation among the structural changes induced by CXL, biomechanical stabilization and long-term effectiveness of the procedure (Lombardo et al. 2014) .
It is known that the disease in paediatric population has a faster progress, I-CXL being an attractive option because of the absence of complications related to the epithelium removal, with a proven efficacy to 15 postoperative months (Buzzonetti & Petrocelli 2015) . The fact that, at the time of CXL, our patients had an average age of 27 and they had been recently diagnosed with keratoconus suggests that the disease was less aggressive, explaining why the I-CXL results were comparable to those of the epi-off CXL. It is also well known that accelerated cross-linking protocols were introduced to reduce the duration of treatment, increasing the illumination intensity. Recent trials comparing the standard protocol of irradiation with various accelerated protocols revealed no significant differences between techniques (Elbaz et al. 2014; Shetty et al. 2015; Ng et al. 2016) . We have exclusively used the accelerated protocol of cross-linking in our clinic for the past 5 years.
All patients examined in the study underwent the same UVA irradiation conditions, 10 mW/cm for 9 min, with only the method of riboflavin impregnation into the corneal stroma being different. We believe that this provides a greater consistency to our results, due to the homogeneity of the used protocol. This is the first study that compares the I-CXL with epi-off CXL which uses an accelerated protocol of irradiation. The total energy of radiation was 5.4 J/ cm² similar to that used in other studies using standard CXL or transepithelial CXL (Bikbova & Bikbov 2014; Bouheraoua et al. 2014; Vinciguerra et al. 2014) . Bouheraoua et al. (2014) suggest increasing the dose of energy by 20% (6.5 J/cm 2 ) in I-CXL because 20% of UVA light is absorbed by the epithelium.
The limitations of our study were its retrospective nature, the relatively small number of patients and only the inclusion of patients with an early-stage disease. Although promising, our results cannot be extrapolated to patients with more advanced stages of disease. Also, we did not assess either the aberometric parameters of the anterior cornea or the topographic morphological indices. However, these limits do not influence the final results of the study.
To conclude, our study demonstrates the I-CXL safety and efficacy comparable with epi-off CXL in adult patients with early-stage progressive keratoconus. The faster visual rehabilitation, the absence of side-effects and the disease stabilization justify this procedure at an early stage of the disease. These patients' long-term follow-up is essential as there is a risk of recurrent progression after a period of disease stabilization.
